Veterinary medicine is a market of several billion dollars. United States there are approximately 150 million dogs and cats. In recent years a growing number of biomedical companies (biotechnology, pharmaceuticals, biopharmaceuticals, medical devices and diagnostics) have tried to made their technologies advance and / or services on the market for animal health. This serves two main goals to achieve as income and to record important data often.

Misunderstandings:

The process is simple. The process to get a product licensed veterinarian is not easy and often requires years of work to get the necessary data to obtain approval and support of the product on the market.

The method is cheap. The cost is the development of drugs or veterinary biological products is not cheap, and can range from several hundred thousand dollars to tens of millions range, depending on the type, disease, etc.

The Food and Drug Administration (FDA) regulates all animal products: FDA Center for Veterinary Medicine regulates drugs. But the U.S. Department of Agriculture (USDA) – Center for Veterinary Biologics regulates diagnostics, vaccines, immune products (immune modulators and stimulants of the immune system) and immunoglobulin products. It also covers the Environmental Protection Agency (EPA) topical products ectoparasites such as fleas and ticks messages.

How to develop and veterinary products:

We encourage you to look for an expert in the field. Too often, trying to find a product for veterinary medicine only, they would develop any expertise or understanding (regulatory, market, etc.) to develop the product efficiently. There are several groups that consulting advice on how to provide products for the veterinary market, development of PET. Some advisers may limit their services to regulatory matters, while others may focus more on clinical trials or commercialization. Find a group that meets your needs is important.

What are the main markets:

It is often difficult to define. Pets (dogs, cats, horses) are often the largest expenditure per species and per visit. Livestock (cattle, pigs, poultry) are the largest volume, but economic pressures are often much per animal. Smaller species (ferrets, rabbits, etc.) is a growing market and the FDA recently approved the minor use Minor Species Act (MUMS Act) on the development of drugs for these species easier.

How to obtain:

1. Set the path of regulation: The first step is to understand which government agency is to monitor the development of the technology or service. Once set, it will be the basis for clinical studies are needed to produce was, labeling, promotional material and other aspects, the product or service. If you are unsure which group will be to oversee the regulation should define a qualified technician for this regulatory strategy.

2. Define the clinical pathway: Next, determine what tests (GLP, GCP) in the target species are required to support the label and licensing. Do not assume that the work of previous laboratory studies on animals unlicensed support your approval process.

3. Define the market strategy and economics: When the way of regulation, clinical path and timing are estimated, it is very important to the market economy that you propose to go to understand. The concept that pet owners are spending nothing on their pets a big mistake. There is a limit, as with any market, the cost of treatment. The construction of the financial justification to avoid financial mistakes and the confidence that the project’s financial measures (ROI, NPV, etc.) needs.

Article Source: http://EzineArticles.com/?expert=Craig_W_Woods